Recalcitrant Hailey-Hailey Disease Successfully Treated with Low-dose Naltrexone(Abstract)

The LDN Conference 2021: 4th - 6th June 2021

Up to 29 CME Credits Available + Sponsor, Exhibitor and Advertiser Opportunities.  [More Details]

Recalcitrant Hailey-Hailey Disease Successfully Treated with Low-dose Naltrexone

J Clin Aesthet Dermatol
13 November 2020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716739/


Hailey-Hailey (HHD), or benign familial chronic pemphigus disease, is a rare autosomal dominant blistering disorder characterized by recurrent vesicles that erode and macerate into weeping and crusting plaques. HHD has been shown to be resistant to several treatment options. Although not yet approved as a treatment for HHD, recent reports have suggested the use of low-dose naltrexone (LDN) as a successful treatment option for controlling recalcitrant HHD. We present a case of a 50-year-old woman with a 20-year history of biopsy-confirmed HHD with recurrent painful and pruritic vesicles and plaques. The patient developed significant clinical improvement of the cutaneous lesions with LDN treatment after only 26 days of treatment. It is important for dermatologists to consider LDN as a viable treatment option for HHD, especially in recalcitrant patients. We suggest this novel treatment as a rapidly effective option to resistant HHD.

Keywords: Hailey-Hailey disease, recalcitrant Hailey-Hailey disease, low-dose naltrexone, benign familial chronic pemphigus disease, blistering disorders, cutaneous lesions, recalcitrant patients

Keywords supplemented by  Erin Williams, student, St. Louis College of Pharmacy